ELISA: Use at a dilution of 1/1500. Optimal dilutions/concentrations should be determined by the end user.
GTX15059 recognises Streptomycin and dihydrostreptomycin. Does not react with other aminoglycoside antibodies such as gentamicin, kanamycin, etc., other classes of antibodies or milk and serum proteins.
Preservative: 0.05% Sodium Azide; Constituents: PBS
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
The first aminoglycoside was streptomycin, which was created from the fungus like bacterium Streptomyces griseus. Streptomycin's ototoxic potential was recognized quite early. In response, researchers modified the drug's molecule and created dihydrostreptomycin. Unlike its predecessor, dihydrostreptomycin is much more cochleotoxic than it is vestibulotoxic; in fact, it is almost exactly as cochleotoxic as streptomycin is vestibulotoxic. Later, investigators tried to reduce the risk of both toxicities by combining equal amounts of the two drugs, but this only resulted in patients experiencing both toxicities rather than neither.